Gastric and oesophageal cancer trials in Germany

In Germany 57 Also abroad 1283

57 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
Where
Magdeburg
Age
18 years and over
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00
Phase 3Taking people
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Where
Berlin, Chemnitz, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Jena, Kiel, Mainz, Munich, Nuremberg, Ravensburg, Schweinfurt, Ulm, Wolfsburg
Age
18 years and over
People
570 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT07673887 · EU 2025-524557-14-00
Phase 1/2Taking people
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Where
Dresden, Erlangen, Essen, Hamburg, Mannheim, Ulm
Age
18 years and over
People
910 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06324357
Phase 3Taking people
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Where
Berlin, Dresden, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Hanover, Kiel, Leipzig, Mainz, Munich, Nuremberg, Saarbruecken, Schweinfurt, Wolfsburg
Age
18 years and over
People
500 worldwide
Run by
Astellas Pharma Global Development, Inc.
See details and how to joinNCT06901531 · EU 2024-519773-19-00
Phase 2/3Taking people
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Where
Berlin, Frankfurt am Main, Hamburg, Heidelberg, Leipzig, Mainz, Mannheim, Ulm
Age
18 years and over
People
690 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07221149 · EU 2025-523263-37-00
Phase 1Taking people
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Where
Erlangen, Essen, München
Age
18 years and over
People
421 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00
Phase 1Taking people
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Where
Essen
Age
18 years and over
People
340 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213791 · EU 2025-521887-37-00
Phase 1/2Taking people
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Where
Berlin, Deggendorf, Hamburg
Age
18 years and over
People
160 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00
Phase 1/2Taking people
BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours
Where
Bonn, Ulm
Age
18 years and over
People
220 worldwide
Run by
Bold Therapeutics, Inc.
See details and how to joinNCT04421820 · EU 2024-517500-11-00
Phase 1/2Taking people
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Where
Dresden, Düsseldorf, Erdgeschoss, Heidelberg
Age
18 years and over
People
298 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780111 · EU 2024-514273-22-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Frankfurt
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Berlin, Dresden, Heidelberg, Heilbronn, Leipzig, Mainz, Muenster
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 3Taking people
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Where
Berlin, Bonn, Dresden, Frankfurt am Main, Hamburg, Jena, Leipzig, Nuremberg, Tübingen
Age
18 years and over
People
510 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06644781 · EU 2023-509630-19-00
Phase 1Not yet taking people in Germany
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Cologne, Essen
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00
Phase 3Taking people
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Where
Augsburg, Bad Saarow, Berlin, Brunswick, Chemnitz, Duesseldorf, Essen, Frankfurt am Main, Goettingen, Hamburg, Leipzig, Ludwigshafen Am Rhein, Luebeck, Mainz, Mannheim, Regensburg, Tuebingen, Ulm
Age
18 years and over
People
840 worldwide
Run by
AstraZeneca
See details and how to joinNCT06764875 · EU 2024-512583-57-00
Phase 3Taking people
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Where
Augsburg, Berlin, Bonn, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heilbronn, Leipzig, Magdeburg, Mainz, Marburg, Minden, Munich, Stuttgart, Ulm
Age
18 years and over
People
2,130 worldwide
Run by
AstraZeneca
See details and how to joinNCT07431281 · EU 2024-519787-40-00
Phase 1/2Taking people
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Where
Berlin, Essen, Mainz, München, Tübingen
Age
18 years and over
People
1,438 worldwide
Run by
BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00
Phase 1/2Taking people
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Where
Berlin, Düsseldorf, Erdgeschoss, Frankfurt am Main
Age
18 years and over
People
230 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05319730 · EU 2023-505189-26-00
Phase 1/2Taking people
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Where
Düsseldorf, Erdgeschoss, Heidelberg
Age
18 years and over
People
160 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06469944 · EU 2023-509307-33-00
Phase 3Taking people
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Where
Essen, Frankfurt, Mainz, Marburg
Age
18 years and over
People
900 worldwide
Run by
Akeso
See details and how to joinNCT07700979
Phase 2Taking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Berlin, Essen, Hanover, München, Regensburg
Age
18 years to 130 years
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
Phase 1/2Taking people
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Where
Cologne, Esslingen am Neckar, Moers, Nuremberg
Age
18 years and over
People
534 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06128551
No phaseTaking people
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Where
Hamburg, Heilbronn, Munich
Age
18 years and over
People
2,285 worldwide
Run by
Guardant Health, Inc.
See details and how to joinNCT05059444
Phase 2Taking people
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
Where
Cologne, Frankfurt am Main, Gauting, Grosshansdorf, Hamburg, Heidelberg, Leipzig, Mainz, Muenster, Offenbach Am Main, Regensburg, Rheine
Age
18 years to 64 years
People
257 worldwide
Run by
AstraZeneca
See details and how to joinNCT06535607 · EU 2025-523947-36-00
Phase 1/2Taking people
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Where
Düsseldorf, Erdgeschoss, Heidelberg
Age
18 years and over
People
210 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06445972 · EU 2023-509306-29-00